On April 8, 2024 Servier, a science driven company focused on developing transformative precision therapies for patients, reported promising preliminary data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 (Press release, Servier, APR 8, 2024, View Source [SID1234641896]). These submissions also demonstrate Servier’s commitment to its One Innovation Engine approach to scientific advancements.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Research to be presented includes biomarker data from a phase 1 dose escalation study of the anti-CD73 antibody (S095024, Sym024) alone or in combination with anti-PD-1. The data illustrates dose dependent target engagement in the tumor and reveals the potential of anti-CD73 to prevent adenosine-mediated tumor evasion.
"Biomarkers play a critical role in shaping the development of precision medicines, providing profound insights into the mechanisms of action behind therapeutic interventions," said Walid Kamoun, Vice President, Global Head of R&D Oncology at Servier. "As Servier has honed its oncology strategy, we are committed to leveraging our proven patient-selection centric approach to seamlessly connect the preclinical and clinical phases and, ultimately, deliver potentially transformative clinical benefits for patients in need."
Noteworthy, research also includes a Phase 1b multicenter study of anti-TIM3 (S095018, Sym023) in combination with anti-PD1 in patients with advanced/metastatic biliary duct cancer, which illustrates the safety of the combination as well as early anti-tumor activity.
"As a leading force in the rapidly evolving field of oncology, Servier distinguishes itself through a unique advantage: our private governance model. This empowers us to swiftly adapt and implement dynamic strategies, ensuring a sustained competitive edge," stated Claude Bertrand, Executive Vice President of Research and Development and Chief Scientific Officer at Servier. "As we participate in AACR (Free AACR Whitepaper) alongside leading minds in cancer research, we are committed to inspiring scientific advancements for the betterment of patients and survivors from bench to bedside."
To access Servier’s abstracts for AACR (Free AACR Whitepaper), please visit their website.